Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Clinical Stage IV Cutaneous Melanoma AJCC v8: early-phase trial registry
15 of 33 indexed Clinical Stage IV Cutaneous Melanoma AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #463 of 28,707 conditions by registered trial count.
33 US clinical trials · 15 currently recruiting · #463 of 28,707 conditions by registered trial count
Clinical Stage IV Cutaneous Melanoma AJCC v8: 33 US clinical trials tracked, 15 recruiting.
Clinical Stage IV Cutaneous Melanoma AJCC v8 is the subject of 33 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 10 of these trials.
Enrollment posture brief
Registry condition clinical-stage-iv-cutaneous-melanoma-ajcc-v8
OPEN 15 | RECR 45% | LATE 2 | EARLY 28 | RANK #463 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Acute Stroke (45% recruiting · 11 trials)
Clinical Stage IV Cutaneous Melanoma AJCC v8 lists 15 open slots (45% of 33 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Clinical Stage IV Cutaneous Melanoma AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Clinical Stage IV Cutaneous Melanoma AJCC v8 is recruiting above its size-band peers.
15 of 33 indexed trials (45.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Clinical Stage IV Cutaneous Melanoma AJCC v8 research.
National Cancer Institute (NCI) accounts for 10 of 33 trials (30.3%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Clinical Stage IV Cutaneous Melanoma AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 59 among the 33 trials that report a genuine target (sentinel values excluded). 23 of those (69.7%) plan for fewer than 100 participants.
-
Clinical Stage IV Cutaneous Melanoma AJCC v8 research is mostly interventional.
31 interventional and 2 observational studies make up this index (93.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
33 total, page 1 of 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
M.D. Anderson Cancer Center
NCT03819296
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Mayo Clinic
NCT06075524
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
National Cancer Institute (NCI)
NCT05136196
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Mayo Clinic
NCT05269381
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
NCT04511013
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
University of California, Davis
NCT05967533
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Emory University
NCT07155317
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
NCT06391099
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT05039801
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
NCT06265285
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Carlo Contreras
NCT04697576
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
M.D. Anderson Cancer Center
NCT05026983
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Kari Kendra
NCT05588453
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Fred Hutchinson Cancer Center
NCT05098210
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
National Cancer Institute (NCI)
NCT05896839
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI)
NCT02506153
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
National Cancer Institute (NCI)
NCT03698019
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
National Cancer Institute (NCI)
NCT02224781
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
ECOG-ACRIN Cancer Research Group
NCT04462406
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
NCT01989585
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
NCT03025256
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT02298959
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
M.D. Anderson Cancer Center
NCT04645680
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT01644591
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
NCT04007744
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
NCT04940299
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT03175432
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
National Cancer Institute (NCI)
NCT04557956
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Roswell Park Cancer Institute
NCT02650986
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
National Cancer Institute (NCI)
NCT03816332
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
NCT05341349
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
National Cancer Institute (NCI)
NCT03033576
The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients
Ohio State University Comprehensive Cancer Center
NCT05102773
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 12 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Clinical Stage IV Cutaneous Melanoma AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Clinical Stage IV Cutaneous Melanoma AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Clinical Stage IV Cutaneous Melanoma AJCC v8 page
33 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Clinical Stage IV Cutaneous Melanoma AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Clinical Stage IV Cutaneous Melanoma AJCC v8 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Clinical Stage IV Cutaneous Melanoma AJCC v8 condition card totals 33 registered trials; most-linked intervention Biospecimen Collection; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.